{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:14:59Z","timestamp":1784690099976,"version":"3.55.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T00:00:00Z","timestamp":1616284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T00:00:00Z","timestamp":1616284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s10067-021-05665-z","type":"journal-article","created":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T01:03:22Z","timestamp":1616288602000},"page":"2621-2631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["B cells in systemic sclerosis: from pathophysiology to treatment"],"prefix":"10.1007","volume":"40","author":[{"given":"Konstantinos","family":"Melissaropoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8027-3655","authenticated-orcid":false,"given":"Dimitrios","family":"Daoussis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,21]]},"reference":[{"key":"5665_CR1","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","volume":"51","author":"M Elhai","year":"2012","unstructured":"Elhai M, Meune C, Avouac J, Kahan A, Allanore Y (2012) Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology 51:1017\u20131026. https:\/\/doi.org\/10.1093\/rheumatology\/ker269","journal-title":"Rheumatology"},{"key":"5665_CR2","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMra0806188","volume":"360","author":"A Gabrielli","year":"2009","unstructured":"Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360:1989\u20132003. https:\/\/doi.org\/10.1056\/NEJMra0806188","journal-title":"N Engl J Med"},{"key":"5665_CR3","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390:1685\u20131699. https:\/\/doi.org\/10.1016\/S0140-6736(17)30933-9","journal-title":"Lancet"},{"key":"5665_CR4","doi-asserted-by":"publisher","unstructured":"Brown M, O\u2019Reilly S (2018) The immunopathogenesis of fibrosis in systemic sclerosis. Clin Exp Immunol. https:\/\/doi.org\/10.1111\/cei.13238","DOI":"10.1111\/cei.13238"},{"key":"5665_CR5","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, M\u00fcller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE (2013) 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative: ACR\/EULAR Classification Criteria for SSc. Arthritis Rheum 65:2737\u20132747. https:\/\/doi.org\/10.1002\/art.38098","journal-title":"Arthritis Rheum"},{"key":"5665_CR6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","volume":"12","author":"S Mehra","year":"2013","unstructured":"Mehra S, Walker J, Patterson K, Fritzler MJ (2013) Autoantibodies in systemic sclerosis. Autoimmun Rev 12:340\u2013354. https:\/\/doi.org\/10.1016\/j.autrev.2012.05.011","journal-title":"Autoimmun Rev"},{"key":"5665_CR7","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.4049\/jimmunol.168.7.3649","volume":"168","author":"LI Sakkas","year":"2002","unstructured":"Sakkas LI, Xu B, Artlett CM, Lu S, Jimenez SA, Platsoucas CD (2002) Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 168:3649\u20133659. https:\/\/doi.org\/10.4049\/jimmunol.168.7.3649","journal-title":"J Immunol"},{"key":"5665_CR8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s11882-014-0434-8","volume":"14","author":"H Eibel","year":"2014","unstructured":"Eibel H, Kraus H, Sic H, Kienzler AK, Rizzi M (2014) B cell biology: an overview. Curr Allergy Asthma Rep 14:434. https:\/\/doi.org\/10.1007\/s11882-014-0434-8","journal-title":"Curr Allergy Asthma Rep"},{"key":"5665_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2901","volume":"11","author":"N Baumgarth","year":"2011","unstructured":"Baumgarth N (2011) The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat Rev Immunol 11:34\u201346. https:\/\/doi.org\/10.1038\/nri2901","journal-title":"Nat Rev Immunol"},{"key":"5665_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.coi.2008.03.014","volume":"20","author":"D Allman","year":"2008","unstructured":"Allman D, Pillai S (2008) Peripheral B cell subsets. Curr Opin Immunol 20:149\u2013157. https:\/\/doi.org\/10.1016\/j.coi.2008.03.014","journal-title":"Curr Opin Immunol"},{"key":"5665_CR11","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","volume":"42","author":"EC Rosser","year":"2015","unstructured":"Rosser EC, Mauri C (2015) Regulatory B cells: origin, phenotype, and function. Immunity 42:607\u2013612. https:\/\/doi.org\/10.1016\/j.immuni.2015.04.005","journal-title":"Immunity"},{"key":"5665_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.molimm.2004.04.008","volume":"41","author":"J Dalporto","year":"2004","unstructured":"Dalporto J (2004) B cell antigen receptor signaling 101. Mol Immunol 41:599\u2013613. https:\/\/doi.org\/10.1016\/j.molimm.2004.04.008","journal-title":"Mol Immunol"},{"key":"5665_CR13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.immuni.2008.04.007","volume":"28","author":"NE Harwood","year":"2008","unstructured":"Harwood NE, Batista FD (2008) New insights into the early molecular events underlying B cell activation. Immunity 28:609\u2013619. https:\/\/doi.org\/10.1016\/j.immuni.2008.04.007","journal-title":"Immunity"},{"key":"5665_CR14","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.molimm.2010.12.007","volume":"48","author":"T Kurosaki","year":"2011","unstructured":"Kurosaki T (2011) Regulation of BCR signaling. Mol Immunol 48:1287\u20131291. https:\/\/doi.org\/10.1016\/j.molimm.2010.12.007","journal-title":"Mol Immunol"},{"key":"5665_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2302\/kjm.49.1","volume":"49","author":"TF Tedder","year":"2000","unstructured":"Tedder TF, Sato S, Poe JC, Fujimoto M (2000) CD19 and CD22 regulate a B lymphocyte signal transduction pathway that contributes to autoimmunity. Keio J Med 49:1\u201313. https:\/\/doi.org\/10.2302\/kjm.49.1","journal-title":"Keio J Med"},{"key":"5665_CR16","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S0952-7915(96)80128-2","volume":"8","author":"GM Doody","year":"1996","unstructured":"Doody GM, Dempsey PW, Fearon DT (1996) Activation of B lymphocytes: integrating signals from CD19, CD22 and Fc\u03b3RIIb1. Curr Opin Immunol 8:378\u2013382. https:\/\/doi.org\/10.1016\/S0952-7915(96)80128-2","journal-title":"Curr Opin Immunol"},{"key":"5665_CR17","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.4049\/jimmunol.0802501","volume":"182","author":"JK Whitmire","year":"2009","unstructured":"Whitmire JK, Asano MS, Kaech SM, Sarkar S, Hannum LG, Shlomchik MJ, Ahmed R (2009) Requirement of B cells for generating CD4+ T cell memory. J Immunol 182:1868\u20131876. https:\/\/doi.org\/10.4049\/jimmunol.0802501","journal-title":"J Immunol"},{"key":"5665_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","volume":"21","author":"F Mackay","year":"2003","unstructured":"Mackay F, Schneider P, Rennert P, Browning J (2003) BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol 21:231\u2013264. https:\/\/doi.org\/10.1146\/annurev.immunol.21.120601.141152","journal-title":"Annu Rev Immunol"},{"key":"5665_CR19","first-page":"1374","volume":"301","author":"H Wardemann","year":"2003","unstructured":"Wardemann H, Yurasov S, Schaefer A et al (2003) Predominant autoantibody production by early human B cell precursors. Sci New Ser 301:1374\u20131377","journal-title":"Sci New Ser"},{"key":"5665_CR20","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.coi.2011.10.007","volume":"23","author":"S Pillai","year":"2011","unstructured":"Pillai S, Mattoo H, Cariappa A (2011) B cells and autoimmunity. Curr Opin Immunol 23:721\u2013731. https:\/\/doi.org\/10.1016\/j.coi.2011.10.007","journal-title":"Curr Opin Immunol"},{"key":"5665_CR21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/imr.12813","volume":"292","author":"JL Platt","year":"2019","unstructured":"Platt JL, Garcia de Mattos Barbosa M, Cascalho M (2019) The five dimensions of B cell tolerance. Immunol Rev 292:180\u2013193. https:\/\/doi.org\/10.1111\/imr.12813","journal-title":"Immunol Rev"},{"key":"5665_CR22","doi-asserted-by":"publisher","unstructured":"Asano Y, Sato S (2013) Animal models of scleroderma: current state and recent development. Curr Rheumatol Rep 15. https:\/\/doi.org\/10.1007\/s11926-013-0382-7","DOI":"10.1007\/s11926-013-0382-7"},{"key":"5665_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/BOR.0000000000000331","volume":"28","author":"RG Marangoni","year":"2016","unstructured":"Marangoni RG, Varga J, Tourtellotte WG (2016) Animal models of scleroderma: recent progress. Curr Opin Rheumatol 28:561\u2013570. https:\/\/doi.org\/10.1097\/BOR.0000000000000331","journal-title":"Curr Opin Rheumatol"},{"key":"5665_CR24","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.vph.2012.12.001","volume":"58","author":"B Maurer","year":"2013","unstructured":"Maurer B, Distler JHW, Distler O (2013) The Fra-2 transgenic mouse model of systemic sclerosis. Vasc Pharmacol 58:194\u2013201. https:\/\/doi.org\/10.1016\/j.vph.2012.12.001","journal-title":"Vasc Pharmacol"},{"key":"5665_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11926-999-0022-4","volume":"1","author":"S Saito","year":"1999","unstructured":"Saito S, Kasturi K, Bona C (1999) Genetic and immunologic features associated with scleroderma-like syndrome of TSK mice. Curr Rheumatol Rep 1:34\u201337","journal-title":"Curr Rheumatol Rep"},{"key":"5665_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.matbio.2014.05.002","volume":"38","author":"KB Long","year":"2014","unstructured":"Long KB, Artlett CM, Blankenhorn EP (2014) Tight skin 2 mice exhibit a novel time line of events leading to increased extracellular matrix deposition and dermal fibrosis. Matrix Biol 38:91\u2013100. https:\/\/doi.org\/10.1016\/j.matbio.2014.05.002","journal-title":"Matrix Biol"},{"key":"5665_CR27","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1006\/jaut.1993.1059","volume":"6","author":"RG Phelps","year":"1993","unstructured":"Phelps RG, Daian C, Shibata S, Fleischmajer R, Bona CA (1993) Induction of skin fibrosis and autoantibodies by infusion of immunocompetent cells from tight skin mice into C57BL\/6 Pa\/Pa mice. J Autoimmun 6:701\u2013718. https:\/\/doi.org\/10.1006\/jaut.1993.1059","journal-title":"J Autoimmun"},{"key":"5665_CR28","doi-asserted-by":"publisher","first-page":"6635","DOI":"10.4049\/jimmunol.165.11.6635","volume":"165","author":"S Sato","year":"2000","unstructured":"Sato S, Hasegawa M, Fujimoto M et al (2000) Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 165:6635\u20136643. https:\/\/doi.org\/10.4049\/jimmunol.165.11.6635","journal-title":"J Immunol"},{"key":"5665_CR29","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI200215078","volume":"109","author":"E Saito","year":"2002","unstructured":"Saito E, Fujimoto M, Hasegawa M et al (2002) CD19-Dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 109:1453\u20131462. https:\/\/doi.org\/10.1172\/JCI200215078","journal-title":"J Clin Invest"},{"key":"5665_CR30","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0002-9440(10)63328-7","volume":"165","author":"N Asano","year":"2004","unstructured":"Asano N, Fujimoto M, Yazawa N, Shirasawa S, Hasegawa M, Okochi H, Tamaki K, Tedder TF, Sato S (2004) B lymphocyte signaling established by the CD19\/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol 165:641\u2013650. https:\/\/doi.org\/10.1016\/S0002-9440(10)63328-7","journal-title":"Am J Pathol"},{"key":"5665_CR31","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1365-2249.2009.04059.x","volume":"159","author":"M Odaka","year":"2010","unstructured":"Odaka M, Hasegawa M, Hamaguchi Y et al (2010) Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis. Clin Exp Immunol 159:176\u2013184. https:\/\/doi.org\/10.1111\/j.1365-2249.2009.04059.x","journal-title":"Clin Exp Immunol"},{"key":"5665_CR32","doi-asserted-by":"publisher","first-page":"954","DOI":"10.2353\/ajpath.2006.060205","volume":"169","author":"M Hasegawa","year":"2006","unstructured":"Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, Matsushita T, Matsushita Y, Horikawa M, Komura K, Takehara K, Sato S, Tedder TF (2006) B-Lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 169:954\u2013966. https:\/\/doi.org\/10.2353\/ajpath.2006.060205","journal-title":"Am J Pathol"},{"key":"5665_CR33","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1038\/sj.jid.5700919","volume":"127","author":"T Matsushita","year":"2007","unstructured":"Matsushita T, Fujimoto M, Hasegawa M, Matsushita Y, Komura K, Ogawa F, Watanabe R, Takehara K, Sato S (2007) BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. J Invest Dermatol 127:2772\u20132780. https:\/\/doi.org\/10.1038\/sj.jid.5700919","journal-title":"J Invest Dermatol"},{"key":"5665_CR34","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1046\/j.1523-1747.1999.00528.x","volume":"112","author":"T Yamamoto","year":"1999","unstructured":"Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, Nishioka K (1999) Animal model of sclerotic skin. I: local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 112:456\u2013462. https:\/\/doi.org\/10.1046\/j.1523-1747.1999.00528.x","journal-title":"J Invest Dermatol"},{"key":"5665_CR35","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2353\/ajpath.2008.071049","volume":"172","author":"A Yoshizaki","year":"2008","unstructured":"Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Tedder TF, Sato S (2008) CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 172:1650\u20131663. https:\/\/doi.org\/10.2353\/ajpath.2008.071049","journal-title":"Am J Pathol"},{"key":"5665_CR36","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1002\/art.23995","volume":"58","author":"K Komura","year":"2008","unstructured":"Komura K, Yanaba K, Horikawa M, Ogawa F, Fujimoto M, Tedder TF, Sato S (2008) CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. Arthritis Rheum 58:3574\u20133584. https:\/\/doi.org\/10.1002\/art.23995","journal-title":"Arthritis Rheum"},{"key":"5665_CR37","doi-asserted-by":"publisher","first-page":"eaas9944","DOI":"10.1126\/sciadv.aas9944","volume":"4","author":"T Matsushita","year":"2018","unstructured":"Matsushita T, Kobayashi T, Mizumaki K et al (2018) BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance. Sci Adv 4:eaas9944. https:\/\/doi.org\/10.1126\/sciadv.aas9944","journal-title":"Sci Adv"},{"key":"5665_CR38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fimmu.2017.00053","volume":"8","author":"S Sanges","year":"2017","unstructured":"Sanges S, Jendoubi M, Kavian N, Hauspie C, Speca S, Crave JC, Guerrier T, Lef\u00e8vre G, Sobanski V, Savina A, Hachulla E, Hatron PY, Labalette M, Batteux F, Dubucquoi S, Launay D (2017) B cell homeostasis and functional properties are altered in an hypochlorous acid-induced murine model of systemic sclerosis. Front Immunol 8:8. https:\/\/doi.org\/10.3389\/fimmu.2017.00053","journal-title":"Front Immunol"},{"key":"5665_CR39","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jdermsci.2019.12.007","volume":"97","author":"C Zhao","year":"2020","unstructured":"Zhao C, Matsushita T, Ha Nguyen VT, Tennichi M, Fujimoto M, Takehara K, Hamaguchi Y (2020) CD22 and CD72 contribute to the development of scleroderma in a murine model. J Dermatol Sci 97:66\u201376. https:\/\/doi.org\/10.1016\/j.jdermsci.2019.12.007","journal-title":"J Dermatol Sci"},{"key":"5665_CR40","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/art.20274","volume":"50","author":"S Sato","year":"2004","unstructured":"Sato S, Fujimoto M, Hasegawa M, Takehara K (2004) Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 50:1918\u20131927. https:\/\/doi.org\/10.1002\/art.20274","journal-title":"Arthritis Rheum"},{"key":"5665_CR41","doi-asserted-by":"publisher","unstructured":"Soto L, Ferrier A, Aravena O et al (2015) Systemic sclerosis patients present alterations in the expression of molecules involved in B-cell regulation. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2015.00496","DOI":"10.3389\/fimmu.2015.00496"},{"key":"5665_CR42","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/art.39437","volume":"68","author":"A Mavropoulos","year":"2016","unstructured":"Mavropoulos A, Simopoulou T, Varna A, Liaskos C, Katsiari CG, Bogdanos DP, Sakkas LI (2016) Breg cells are numerically decreased and functionally impaired in patients with systemic sclerosis: BREG CELLS IN SYSTEMIC SCLEROSIS. Arthritis Rheum 68:494\u2013504. https:\/\/doi.org\/10.1002\/art.39437","journal-title":"Arthritis Rheum"},{"key":"5665_CR43","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.autrev.2017.10.015","volume":"17","author":"A Forestier","year":"2018","unstructured":"Forestier A, Guerrier T, Jouvray M, Giovannelli J, Lef\u00e8vre G, Sobanski V, Hauspie C, Hachulla E, Hatron PY, Z\u00e9phir H, Vermersch P, Labalette M, Launay D, Dubucquoi S (2018) Altered B lymphocyte homeostasis and functions in systemic sclerosis. Autoimmun Rev 17:244\u2013255. https:\/\/doi.org\/10.1016\/j.autrev.2017.10.015","journal-title":"Autoimmun Rev"},{"key":"5665_CR44","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/art.40390","volume":"70","author":"TE Taher","year":"2018","unstructured":"Taher TE, Ong VH, Bystrom J, Hillion S, Simon Q, Denton CP, Pers JO, Abraham DJ, Mageed RA (2018) Association of defective regulation of autoreactive interleukin-6-producing transitional B lymphocytes with disease in patients with systemic sclerosis. Arthritis Rheum 70:450\u2013461. https:\/\/doi.org\/10.1002\/art.40390","journal-title":"Arthritis Rheum"},{"key":"5665_CR45","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/rheumatology\/kev331","volume":"55","author":"T Matsushita","year":"2016","unstructured":"Matsushita T, Hamaguchi Y, Hasegawa M, Takehara K, Fujimoto M (2016) Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity. Rheumatology 55:263\u2013267. https:\/\/doi.org\/10.1093\/rheumatology\/kev331","journal-title":"Rheumatology"},{"key":"5665_CR46","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/art.40016","volume":"69","author":"N Dumoitier","year":"2017","unstructured":"Dumoitier N, Chaigne B, R\u00e9gent A, Lofek S, Mhibik M, Dorfm\u00fcller P, Terrier B, London J, B\u00e9rezn\u00e9 A, Tamas N, Varin-Blank N, Mouthon L (2017) Scleroderma peripheral B lymphocytes secrete interleukin-6 and transforming growth factor \u03b2 and activate fibroblasts. Arthritis Rheum 69:1078\u20131089. https:\/\/doi.org\/10.1002\/art.40016","journal-title":"Arthritis Rheum"},{"key":"5665_CR47","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/art.21526","volume":"54","author":"T Matsushita","year":"2006","unstructured":"Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S (2006) Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 54:192\u2013201. https:\/\/doi.org\/10.1002\/art.21526","journal-title":"Arthritis Rheum"},{"key":"5665_CR48","first-page":"2056","volume":"34","author":"T Matsushita","year":"2007","unstructured":"Matsushita T, Fujimoto M, Hasegawa M, Tanaka C, Kumada S, Ogawa F, Takehara K, Sato S (2007) Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol 34:2056\u20132062","journal-title":"J Rheumatol"},{"key":"5665_CR49","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.3899\/jrheum.100454","volume":"37","author":"M Bielecki","year":"2010","unstructured":"Bielecki M, Kowal K, Lapinska A et al (2010) Increased production of a proliferation-inducing ligand (APRIL) by peripheral blood mononuclear cells is associated with antitopoisomerase I antibody and more severe disease in systemic sclerosis. J Rheumatol 37:2286\u20132289. https:\/\/doi.org\/10.3899\/jrheum.100454","journal-title":"J Rheumatol"},{"key":"5665_CR50","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s00296-018-4076-3","volume":"38","author":"K Melissaropoulos","year":"2018","unstructured":"Melissaropoulos K, Liossis S-N (2018) Decreased CD22 expression and intracellular signaling aberrations in B cells of patients with systemic sclerosis. Rheumatol Int 38:1225\u20131234. https:\/\/doi.org\/10.1007\/s00296-018-4076-3","journal-title":"Rheumatol Int"},{"key":"5665_CR51","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1002\/art.20674","volume":"50","author":"N Tsuchiya","year":"2004","unstructured":"Tsuchiya N, Kuroki K, Fujimoto M, Murakami Y, Tedder TF, Tokunaga K, Takehara K, Sato S (2004) Association of a functionalCD19 polymorphism with susceptibility to systemic sclerosis. Arthritis Rheum 50:4002\u20134007. https:\/\/doi.org\/10.1002\/art.20674","journal-title":"Arthritis Rheum"},{"key":"5665_CR52","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1399-0039.2007.00801.x","volume":"69","author":"Y Hitomi","year":"2007","unstructured":"Hitomi Y, Tsuchiya N, Hasegawa M et al (2007) Association of CD22 gene polymorphism with susceptibility to limited cutaneous systemic sclerosis. Tissue Antigens 69:242\u2013249. https:\/\/doi.org\/10.1111\/j.1399-0039.2007.00801.x","journal-title":"Tissue Antigens"},{"key":"5665_CR53","unstructured":"Yagi-Numata N, Matsushita T, Takehara K, Hamaguchi Y (2019) Increased expression levels of Fc\u03b3RIIB on na\u00efve and double- negative memory B cells in patients with systemic sclerosis. Clin Exp Rheumatol 37 Suppl 119:23\u201331"},{"key":"5665_CR54","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1002\/art.22847","volume":"56","author":"R Lafyatis","year":"2007","unstructured":"Lafyatis R, O\u2019Hara C, Feghali-Bostwick CA, Matteson E (2007) B cell infiltration in systemic sclerosis\u2013associated interstitial lung disease. Arthritis Rheum 56:3167\u20133168. https:\/\/doi.org\/10.1002\/art.22847","journal-title":"Arthritis Rheum"},{"key":"5665_CR55","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1752-699X.2010.00228.x","volume":"6","author":"M De Santis","year":"2012","unstructured":"De Santis M, Bosello SL, Peluso G et al (2012) Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease: scleroderma interstitial lung disease. Clin Respir J 6:9\u201317. https:\/\/doi.org\/10.1111\/j.1752-699X.2010.00228.x","journal-title":"Clin Respir J"},{"key":"5665_CR56","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/art.1780200410","volume":"20","author":"R Fleischmajer","year":"1977","unstructured":"Fleischmajer R, Perlish JS, Reeves JRT (1977) Cellular infiltrates in scleroderma skin. Arthritis Rheum 20:975\u2013984. https:\/\/doi.org\/10.1002\/art.1780200410","journal-title":"Arthritis Rheum"},{"key":"5665_CR57","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/art.1780270607","volume":"27","author":"AD Roumm","year":"1984","unstructured":"Roumm AD, Whiteside TL, Medsger TA, Rodnan GP (1984) Lymphocytes in the skin of patients with progressive systemic sclerosis. Arthritis Rheum 27:645\u2013653. https:\/\/doi.org\/10.1002\/art.1780270607","journal-title":"Arthritis Rheum"},{"key":"5665_CR58","doi-asserted-by":"publisher","first-page":"12319","DOI":"10.1073\/pnas.1635114100","volume":"100","author":"ML Whitfield","year":"2003","unstructured":"Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, Connolly MK (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci 100:12319\u201312324. https:\/\/doi.org\/10.1073\/pnas.1635114100","journal-title":"Proc Natl Acad Sci"},{"key":"5665_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002696","volume":"3","author":"A Milano","year":"2008","unstructured":"Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, Whitfield ML (2008) Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 3:e2696. https:\/\/doi.org\/10.1371\/journal.pone.0002696","journal-title":"PLoS ONE"},{"key":"5665_CR60","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/annrheumdis-2019-215894","volume":"79","author":"B Skaug","year":"2020","unstructured":"Skaug B, Khanna D, Swindell WR, Hinchcliff ME, Frech TM, Steen VD, Hant FN, Gordon JK, Shah AA, Zhu L, Zheng WJ, Browning JL, Barron AMS, Wu M, Visvanathan S, Baum P, Franks JM, Whitfield ML, Shanmugam VK, Domsic RT, Castelino FV, Bernstein EJ, Wareing N, Lyons MA, Ying J, Charles J, Mayes MD, Assassi S (2020) Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Ann Rheum Dis 79:379\u2013386. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215894","journal-title":"Ann Rheum Dis"},{"key":"5665_CR61","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13075-018-1569-0","volume":"20","author":"S Bosello","year":"2018","unstructured":"Bosello S, Angelucci C, Lama G, Alivernini S, Proietti G, Tolusso B, Sica G, Gremese E, Ferraccioli G (2018) Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression. Arthritis Res Ther 20:75. https:\/\/doi.org\/10.1186\/s13075-018-1569-0","journal-title":"Arthritis Res Ther"},{"key":"5665_CR62","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1586\/eci.11.39","volume":"7","author":"A Usategui","year":"2011","unstructured":"Usategui A, del Rey MJ, Pablos JL (2011) Fibroblast abnormalities in the pathogenesis of systemic sclerosis. Expert Rev Clin Immunol 7:491\u2013498. https:\/\/doi.org\/10.1586\/eci.11.39","journal-title":"Expert Rev Clin Immunol"},{"key":"5665_CR63","doi-asserted-by":"publisher","first-page":"102526","DOI":"10.1016\/j.jaut.2020.102526","volume":"113","author":"JC Worrell","year":"2020","unstructured":"Worrell JC, O\u2019Reilly S (2020) Bi-directional communication: conversations between fibroblasts and immune cells in systemic sclerosis. J Autoimmun 113:102526. https:\/\/doi.org\/10.1016\/j.jaut.2020.102526","journal-title":"J Autoimmun"},{"key":"5665_CR64","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/ar4392","volume":"15","author":"D Daoussis","year":"2013","unstructured":"Daoussis D, Liossis S-NC (2013) B cells tell scleroderma fibroblasts to produce collagen. Arthritis Res Ther 15:125. https:\/\/doi.org\/10.1186\/ar4392","journal-title":"Arthritis Res Ther"},{"key":"5665_CR65","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/ard.2008.104299","volume":"69","author":"B Terrier","year":"2010","unstructured":"Terrier B, Tamby MC, Camoin L, Guilpain P, B\u00e9rezn\u00e9 A, Tamas N, Broussard C, Hotellier F, Humbert M, Simonneau G, Guillevin L, Mouthon L (2010) Antifibroblast antibodies from systemic sclerosis patients bind to \u03b1-enolase and are associated with interstitial lung disease. Ann Rheum Dis 69:428\u2013433. https:\/\/doi.org\/10.1136\/ard.2008.104299","journal-title":"Ann Rheum Dis"},{"key":"5665_CR66","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1002\/art.20515","volume":"50","author":"J H\u00e9nault","year":"2004","unstructured":"H\u00e9nault J, Tremblay M, Cl\u00e9ment I, Raymond Y, Sen\u00e9cal JL (2004) Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis: antifibroblast autoantibodies in SSc. Arthritis Rheum 50:3265\u20133274. https:\/\/doi.org\/10.1002\/art.20515","journal-title":"Arthritis Rheum"},{"key":"5665_CR67","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1002\/art.24049","volume":"58","author":"S Fineschi","year":"2008","unstructured":"Fineschi S, Goffin L, Rezzonico R, Cozzi F, Dayer JM, Meroni PL, Chizzolini C (2008) Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. Arthritis Rheum 58:3913\u20133923. https:\/\/doi.org\/10.1002\/art.24049","journal-title":"Arthritis Rheum"},{"key":"5665_CR68","unstructured":"Baroni SS, Luchetti M, Fraticelli P et al (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 10"},{"key":"5665_CR69","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/art.24365","volume":"60","author":"N Loizos","year":"2009","unstructured":"Loizos N, LaRiccia L, Weiner J et al (2009) Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor \u03b1 in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum 60:1145\u20131151. https:\/\/doi.org\/10.1002\/art.24365","journal-title":"Arthritis Rheum"},{"key":"5665_CR70","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/art.24381","volume":"60","author":"J-F Classen","year":"2009","unstructured":"Classen J-F, Henrohn D, Rorsman F, Lennartsson J, Lauwerys BR, Wikstr\u00f6m G, Rorsman C, Lenglez S, Franck-Larsson K, Tomasi JP, K\u00e4mpe O, Vanthuyne M, Houssiau FA, Demoulin JB (2009) Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 60:1137\u20131144. https:\/\/doi.org\/10.1002\/art.24381","journal-title":"Arthritis Rheum"},{"key":"5665_CR71","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1046\/j.1523-1747.2003.12097.x","volume":"120","author":"S Sato","year":"2003","unstructured":"Sato S, Hayakawa I, Hasegawa M, Takehara K, Fujimoto M (2003) Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 120:542\u2013547. https:\/\/doi.org\/10.1046\/j.1523-1747.2003.12097.x","journal-title":"J Invest Dermatol"},{"key":"5665_CR72","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.4049\/jimmunol.175.7.4555","volume":"175","author":"X Zhou","year":"2005","unstructured":"Zhou X, Tan FK, Milewicz DM, Guo X, Bona CA, Arnett FC (2005) Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-pathway to recapitulate the \u201cscleroderma phenotype\u201d. J Immunol 175:4555\u20134560. https:\/\/doi.org\/10.4049\/jimmunol.175.7.4555","journal-title":"J Immunol"},{"key":"5665_CR73","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S0923-1811(01)00128-1","volume":"27","author":"S Sato","year":"2001","unstructured":"Sato S, Hasegawa M, Takehara K (2001) Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 27:140\u2013146. https:\/\/doi.org\/10.1016\/S0923-1811(01)00128-1","journal-title":"J Dermatol Sci"},{"key":"5665_CR74","doi-asserted-by":"publisher","first-page":"R168","DOI":"10.1186\/ar4352","volume":"15","author":"A Fran\u00e7ois","year":"2013","unstructured":"Fran\u00e7ois A, Chatelus E, Wachsmann D, Sibilia J, Bahram S, Alsaleh G, Gottenberg JE (2013) B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res Ther 15:R168. https:\/\/doi.org\/10.1186\/ar4352","journal-title":"Arthritis Res Ther"},{"key":"5665_CR75","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655\u20132666. https:\/\/doi.org\/10.1056\/NEJMoa055120","journal-title":"N Engl J Med"},{"key":"5665_CR76","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM, Sclerodema Lung Study II Investigators (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:708\u2013719. https:\/\/doi.org\/10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"key":"5665_CR77","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/01.bor.0000434669.32150.ac","volume":"25","author":"JM Van Laar","year":"2013","unstructured":"Van Laar JM, Sullivan K (2013) Stem cell transplantation in systemic sclerosis. Curr Opin Rheumatol 25:719\u2013725. https:\/\/doi.org\/10.1097\/01.bor.0000434669.32150.ac","journal-title":"Curr Opin Rheumatol"},{"key":"5665_CR78","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St. Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE (2018) Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 378:35\u201347","journal-title":"N Engl J Med"},{"key":"5665_CR79","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13075-019-1889-8","volume":"21","author":"M Gernert","year":"2019","unstructured":"Gernert M, Tony H-P, Schwaneck EC, Gadeholt O, Schmalzing M (2019) Autologous hematopoietic stem cell transplantation in systemic sclerosis induces long-lasting changes in B cell homeostasis toward an anti-inflammatory B cell cytokine pattern. Arthritis Res Ther 21:106. https:\/\/doi.org\/10.1186\/s13075-019-1889-8","journal-title":"Arthritis Res Ther"},{"key":"5665_CR80","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00296-020-04515-6","volume":"40","author":"DP Misra","year":"2020","unstructured":"Misra DP, Ahmed S, Agarwal V (2020) Is biological therapy in systemic sclerosis the answer? Rheumatol Int 40:679\u2013694. https:\/\/doi.org\/10.1007\/s00296-020-04515-6","journal-title":"Rheumatol Int"},{"key":"5665_CR81","doi-asserted-by":"publisher","first-page":"102453","DOI":"10.1016\/j.autrev.2019.102453","volume":"19","author":"M Bellan","year":"2020","unstructured":"Bellan M, Patrucco F, Barone-Adesi F, Gavelli F, Castello LM, Nerviani A, Andreoli L, Cavagna L, Pirisi M, Sainaghi PP (2020) Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: a systematic review. Autoimmun Rev 19:102453. https:\/\/doi.org\/10.1016\/j.autrev.2019.102453","journal-title":"Autoimmun Rev"},{"key":"5665_CR82","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","volume":"49","author":"D Daoussis","year":"2010","unstructured":"Daoussis D, Liossis S-NC, Tsamandas AC et al (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 49:271\u2013280. https:\/\/doi.org\/10.1093\/rheumatology\/kep093","journal-title":"Rheumatology"},{"key":"5665_CR83","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","volume":"57","author":"G Sircar","year":"2018","unstructured":"Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P (2018) Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology 57:2106\u20132113. https:\/\/doi.org\/10.1093\/rheumatology\/key213","journal-title":"Rheumatology"},{"key":"5665_CR84","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000384","volume":"3","author":"M Boonstra","year":"2017","unstructured":"Boonstra M, Meijs J, Dorj\u00e9e AL, Marsan NA, Schouffoer A, Ninaber MK, Quint KD, Bonte-Mineur F, Huizinga TWJ, Scherer HU, de Vries-Bouwstra JK (2017) Rituximab in early systemic sclerosis. RMD Open 3:e000384. https:\/\/doi.org\/10.1136\/rmdopen-2016-000384","journal-title":"RMD Open"},{"key":"5665_CR85","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/art.24249","volume":"60","author":"R Lafyatis","year":"2009","unstructured":"Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60:578\u2013583. https:\/\/doi.org\/10.1002\/art.24249","journal-title":"Arthritis Rheum"},{"key":"5665_CR86","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/ard.2008.095463","volume":"69","author":"V Smith","year":"2010","unstructured":"Smith V, Van Praet JT, Vandooren B et al (2010) Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 69:193\u2013197. https:\/\/doi.org\/10.1136\/ard.2008.095463","journal-title":"Ann Rheum Dis"},{"key":"5665_CR87","doi-asserted-by":"publisher","first-page":"R54","DOI":"10.1186\/ar2965","volume":"12","author":"S Bosello","year":"2010","unstructured":"Bosello S, De Santis M, Lama G et al (2010) B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 12:R54. https:\/\/doi.org\/10.1186\/ar2965","journal-title":"Arthritis Res Ther"},{"key":"5665_CR88","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.autrev.2017.12.010","volume":"17","author":"M Thiebaut","year":"2018","unstructured":"Thiebaut M, Launay D, Rivi\u00e8re S, Mah\u00e9vas T, Bellakhal S, Hachulla E, Fain O, Mekinian A (2018) Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmun Rev 17:582\u2013587. https:\/\/doi.org\/10.1016\/j.autrev.2017.12.010","journal-title":"Autoimmun Rev"},{"key":"5665_CR89","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/17843286.2017.1372244","volume":"73","author":"K Melsens","year":"2018","unstructured":"Melsens K, Vandecasteele E, Deschepper E, Badot V, Blockmans D, Brusselle G, de Langhe E, de Pauw M, Debusschere C, Decuman S, Deroo L, Houssiau F, Lenaerts J, Piette Y, Thevissen K, Vanthuyne M, Westhovens R, Wijnant S, de Keyser F, Smith V (2018) Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis. Acta Clin Belg 73:119\u2013125. https:\/\/doi.org\/10.1080\/17843286.2017.1372244","journal-title":"Acta Clin Belg"},{"key":"5665_CR90","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.semarthrit.2020.08.004","volume":"50","author":"J Narv\u00e1ez","year":"2020","unstructured":"Narv\u00e1ez J, LLuch J, Molina-Molina M et al (2020) Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression. Semin Arthritis Rheum 50:977\u2013987. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.08.004","journal-title":"Semin Arthritis Rheum"},{"key":"5665_CR91","first-page":"S17","volume":"30","author":"D Daoussis","year":"2012","unstructured":"Daoussis D, Liossis S-NC, Tsamandas AC et al (2012) Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 30:S17\u2013S22","journal-title":"Clin Exp Rheumatol"},{"key":"5665_CR92","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","volume":"46","author":"D Daoussis","year":"2017","unstructured":"Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T, Georgiou P, Andonopoulos AP, Drosos AA, Sakkas L, Liossis SN (2017) A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum 46:625\u2013631. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.10.003","journal-title":"Semin Arthritis Rheum"},{"key":"5665_CR93","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.semarthrit.2014.09.002","volume":"44","author":"SL Bosello","year":"2015","unstructured":"Bosello SL, De Luca G, Rucco M et al (2015) Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum 44:428\u2013436. https:\/\/doi.org\/10.1016\/j.semarthrit.2014.09.002","journal-title":"Semin Arthritis Rheum"},{"key":"5665_CR94","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","volume":"74","author":"S Jordan","year":"2015","unstructured":"Jordan S, Distler JHW, Maurer B, Huscher D, van Laar J, Allanore Y, Distler O, EUSTAR Rituximab study group (2015) Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 74:1188\u20131194. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204522","journal-title":"Ann Rheum Dis"},{"key":"5665_CR95","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","volume":"78","author":"M Elhai","year":"2019","unstructured":"Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellv\u00ed I, Air\u00f3 P, Vettori S, de Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, L\u00f3pez-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanore Y, for EUSTAR network (2019) Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis 78:979\u2013987. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214816","journal-title":"Ann Rheum Dis"},{"key":"5665_CR96","doi-asserted-by":"publisher","unstructured":"Goswami RP, Ray A, Chatterjee M et al (2020) Rituximab in the treatment of systemic sclerosis\u2013related interstitial lung disease: a systematic review and meta-analysis. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keaa550","DOI":"10.1093\/rheumatology\/keaa550"},{"key":"5665_CR97","doi-asserted-by":"publisher","first-page":"106389","DOI":"10.1016\/j.intimp.2020.106389","volume":"83","author":"R Tang","year":"2020","unstructured":"Tang R, Yu J, Shi Y, Zou P, Zeng Z, Tang B, Wang Y, Ling G, Luo M, Xiao R (2020) Safety and efficacy of rituximab in systemic sclerosis: a systematic review and meta-analysis. Int Immunopharmacol 83:106389. https:\/\/doi.org\/10.1016\/j.intimp.2020.106389","journal-title":"Int Immunopharmacol"},{"key":"5665_CR98","doi-asserted-by":"publisher","unstructured":"Hughes M, Denton CP, Khanna D (2020) Rituximab for the treatment of systemic sclerosis-interstitial lung disease. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keaa675","DOI":"10.1093\/rheumatology\/keaa675"},{"key":"5665_CR99","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/art.40358","volume":"70","author":"JK Gordon","year":"2018","unstructured":"Gordon JK, Martyanov V, Franks JM, Bernstein EJ, Szymonifka J, Magro C, Wildman HF, Wood TA, Whitfield ML, Spiera RF (2018) Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial. Arthritis Rheum 70:308\u2013316. https:\/\/doi.org\/10.1002\/art.40358","journal-title":"Arthritis Rheum"},{"key":"5665_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13075-016-1021-2","volume":"18","author":"E Schiopu","year":"2016","unstructured":"Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K, Yao W, Li J, Streicher K, McKeever K, White B, Katz E, Drappa J, Sweeny S, Herbst R (2016) Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther 18:1\u201314. https:\/\/doi.org\/10.1186\/S13075-016-1021-2","journal-title":"Arthritis Res Ther"},{"key":"5665_CR101","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1002\/art.40656","volume":"70","author":"K Streicher","year":"2018","unstructured":"Streicher K, Sridhar S, Kuziora M, Morehouse CA, Higgs BW, Sebastian Y, Groves CJ, Pilataxi F, Brohawn PZ, Herbst R, Ranade K (2018) Baseline plasma cell gene signature predicts improvement in systemic sclerosis skin scores following treatment with inebilizumab (MEDI-551) and correlates with disease activity in systemic lupus erythematosus and chronic obstructive pulmonary disease. Arthritis Rheum 70:2087\u20132095. https:\/\/doi.org\/10.1002\/art.40656","journal-title":"Arthritis Rheum"},{"key":"5665_CR102","doi-asserted-by":"publisher","first-page":"33","DOI":"10.31138\/mjr.30.1.33","volume":"30","author":"D Daoussis","year":"2019","unstructured":"Daoussis D, Liossis S-N (2019) Treatment of systemic sclerosis associated fibrotic manifestations: current options and future directions. Mediterr J Rheumatol 30:33\u201337. https:\/\/doi.org\/10.31138\/mjr.30.1.33","journal-title":"Mediterr J Rheumatol"},{"key":"5665_CR103","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.2174\/0929867322666150209161224","volume":"22","author":"T Dimitroulas","year":"2015","unstructured":"Dimitroulas T, Daoussis D, Garyfallos A, Sfikakis P, Kitas G (2015) Molecular and cellular pathways as treatment targets for biologic therapies in systemic sclerosis. Curr Med Chem 22:1943\u20131955. https:\/\/doi.org\/10.2174\/0929867322666150209161224","journal-title":"Curr Med Chem"},{"key":"5665_CR104","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s00296-019-04357-x","volume":"39","author":"K Melissaropoulos","year":"2019","unstructured":"Melissaropoulos K, Kraniotis P, Bogdanos D, Dimitroulas T, Sakkas L, Daoussis D (2019) Targeting very early systemic sclerosis: a case-based review. Rheumatol Int 39:1961\u20131970. https:\/\/doi.org\/10.1007\/s00296-019-04357-x","journal-title":"Rheumatol Int"},{"key":"5665_CR105","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00296-019-04350-4","volume":"39","author":"I Antonopoulos","year":"2019","unstructured":"Antonopoulos I, Daoussis D, Lalioti M-E, Markatseli TE, Drosos AA, Taraviras S, Andonopoulos AP, Liossis SNC (2019) B cell depletion treatment decreases CD4+IL4+ and CD4+CD40L+ T cells in patients with systemic sclerosis. Rheumatol Int 39:1889\u20131898. https:\/\/doi.org\/10.1007\/s00296-019-04350-4","journal-title":"Rheumatol Int"},{"key":"5665_CR106","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13075-016-1017-y","volume":"18","author":"D Daoussis","year":"2016","unstructured":"Daoussis D, Tsamandas A, Antonopoulos I, Filippopoulou A, Papachristou DJ, Papachristou NI, Andonopoulos AP, Liossis SN (2016) B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis. Arthritis Res Ther 18:118. https:\/\/doi.org\/10.1186\/s13075-016-1017-y","journal-title":"Arthritis Res Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05665-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05665-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05665-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T16:13:58Z","timestamp":1623255238000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05665-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,21]]},"references-count":106,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["5665"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05665-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,21]]},"assertion":[{"value":"18 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}